SCHEMBL2246851

SCHEMBL2246851

CCCCCCCCCCCCCCCCOC[C@H](CO)OCCCCC(=O)O.C[N+](C)(C)CCOP(=O)([O-])S

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RECQL P46063 1/20 0.62
▸ ADRA1D P25100 1/20 0.53
▸ PTAFR P25105 1/20 0.53
▸ HTR1D P28221 1/20 0.53
▸ HTR2C P28335 1/20 0.53
▸ ADRA1B P35368 1/20 0.53
▸ DRD3 P35462 1/20 0.53
▸ TMEM97 Q5BJF2 1/20 0.53
▸ MAPK1 P28482 5/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ GMNN O75496 3/20 0.52
▸ LMNA P02545 3/20 0.52
▸ BLM P54132 3/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ NPSR1 Q6W5P4 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ PRKD3 O94806 1/20 0.52
▸ PRKCG P05129 1/20 0.52
▸ PRKCB P05771 1/20 0.52
▸ PRKCA P17252 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL704033 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
Vb-201 SCHEMBL2071230 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
SCHEMBL2231559 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
SCHEMBL704034 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
SCHEMBL2232633 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
SCHEMBL2232585 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
Vb-201 SCHEMBL14322398 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
Vb-201 SCHEMBL2071110 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
SCHEMBL20143296 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C
SCHEMBL703690 0.85 RECQL (0.81) RECQLADRA1DPTAFRHTR1DHTR2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110195937-A1 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-11 — — US claimed
US-8999960-B2 Oxidized thiophospholipid compounds and uses thereof VASCULAR BIOGENICS LTD. (IL) 2015-04-07 — — US disclosed
US-20110195937-A1 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2011-08-11 — — US disclosed
EP-2348864-A2 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF Vascular Biogenics Ltd. (IL) 2011-08-03 — — EP disclosed
WO-2010041242-A2 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF VASCULAR BIOGENICS LTD. (IL) 2010-04-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195937-A1 OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF PRDX2, PRDX1, LPO RECQL 1572/4885ADRA1D 2031/4885PTAFR 1508/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback